ArticleCost effectiveness and resource allocation : C/E2025

Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin.

John C Chapola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.